Global Technical Applications Manager, Merck KGaA, DE

Parallel - Meet the Expert Session on CRISPR/Cas: Merck

This session will cover the ins and outs of the CRISPR/Cas technology, and will introduce you to a novel approach: Merck has developed a chemically synthesized two part (tracr/crRNA) CRISPR system, which holds many advantages to the traditional CRISPR/Cas editing system. Think: no cloning! easy to deliver! Immediate genome editing! No off-targets! Fast and cost-effective! The ideal system to start or expand your CRISPR activities.

Speaker at
25-26 January 2018, Bruges, Belgium
27-29 September 2017, Ghent, Belgium